X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
SYNCAR-001, an autologous CD19-targeted CAR-T in combination with STK-009 is a human orthogonal IL-2 cytokine is being evaluated for the treatment of lupus without lymphodepletion.
Lead Product(s): SYNCAR-001,STK-009
Therapeutic Area: Immunology Product Name: SYNCAR-001
Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 26, 2024
Details:
The collaboration aims to support the development of selective IL-10 agonists, which play a key role in immune regulation for the treatment of inflammatory diseases.
Lead Product(s): Undisclosed
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Sanofi
Deal Size: Undisclosed Upfront Cash: $40.0 million
Deal Type: Collaboration January 29, 2024
Details:
STK-012 is the first-in-class alpha/beta biased IL-2 has potential to decouple efficacy and toxicity of IL-2, which is investigated for the treatment of treatment of solid tumors.
Lead Product(s): STK-012,Pembrolizumab
Therapeutic Area: Oncology Product Name: STK-012
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 28, 2023
Details:
STK-009 + SYNCAR-001 is a two-component therapy consisting of SYNCAR-001, a CD19-targeting chimeric antigen receptor T cell (CAR-T) which expresses an engineered IL-2 receptor allowing it to selectively receive a signal from STK-009, an engineered pegylated IL-2 cytokine.
Lead Product(s): SYNCAR-001,STK-009
Therapeutic Area: Oncology Product Name: SYNCAR-001
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 27, 2023
Details:
Proceeds of the financing will be used to advance Synthekine’s differentiated therapeutic pipeline, led by its alpha/beta-biased IL-2 partial agonist, STK-012, which is currently in a Phase 1 clinical trial.
Lead Product(s): STK-012,Pembrolizumab
Therapeutic Area: Oncology Product Name: STK-012
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: The Column Group
Deal Size: $100.0 million Upfront Cash: Undisclosed
Deal Type: Series C Financing January 06, 2023
Details:
In syngeneic tumor models, subcutaneously injected STK-012 mouse surrogate demonstrated reduced toxicities and improved efficacy relative to mouse wild-type IL-2 or a non-α IL-2. In cynomolgus monkeys, acute lung inflammation was induced by aldesleukin and non-α-IL-2.
Lead Product(s): STK-012,Pembrolizumab
Therapeutic Area: Oncology Product Name: STK-012
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 07, 2022
Details:
In non-human primate studies, STK-012 avoided lymphopenia, NK cell activation and CLS induction, which was observed with both aldesleukin and a non-alpha-IL-2 agent.
Lead Product(s): STK-012,Pembrolizumab
Therapeutic Area: Oncology Product Name: STK-012
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 03, 2022
Details:
Preclinical studies demonstrated a mouse surrogate of STK-012 achieved superior tumor regression compared to both wild-type mouse IL-2 and a non-alpha-IL-2 agent, representing a different approach to biasing IL-2.
Lead Product(s): STK-012,Pembrolizumab
Therapeutic Area: Oncology Product Name: STK-012
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 28, 2021
Details:
Synthekine’s therapeutic pipeline is led by its selective IL-2 partial agonist, STK-012, and its orthogonal IL-2 and CD-19 CAR-T system, STK-009 and SYNCAR-001.
Lead Product(s): STK-012
Therapeutic Area: Oncology Product Name: STK-012
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Deerfield Management
Deal Size: $107.5 million Upfront Cash: Undisclosed
Deal Type: Series B Financing June 10, 2021
Details:
Proceeds from this Series A financing will be used to advance Synthekine’s lead therapeutic programs into clinical studies, expand its discovery pipeline and hone its proprietary cytokine engineering platforms.
Lead Product(s): STK-012
Therapeutic Area: Oncology Product Name: STK-012
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Canaan Partners
Deal Size: $82.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing September 17, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
